Amplion Secures Series A Funding Led by Greycroft to Advance Biomarker Intelligence Platform

Recently, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that U.S. biomarker intelligence company Amplion has secured Series A financing, with the amount undisclosed.

This round of financing was led by the investment firm Greycroft, with participation from existing investors, including The Rest Seed Fund under Revolution and Imagen Capital Partners. Greycroft is a New York-based venture capital firm focused on investments in technology startups, internet, and mobile markets. With offices in two of the world’s most important business hubs, New York and Los Angeles, Greycroft provides unique services to facilitate entrepreneurial business collaborations.

Greycroft leverages its extensive network of connections in the media and technology industries to help entrepreneurs gain visibility, build strategic relationships, bring products to market, and establish successful businesses. With over $1 billion in assets under management, Greycroft has made more than 200 investments since its inception in leading companies including Acorns, App Annie, Bird, Botkeeper, Bright Health, Boxed, Braintree, Buddy Media, Everything But The House, Extreme Reach, Huffington Post, and Icertis.

Amplion disclosed that the funds will be used to expand its sales and marketing efforts and accelerate product development.

Amplion, founded in 2013 and headquartered in Oregon, USA, is dedicated to improving patient outcomes through precision medicine. It provides evidence-based biomarker intelligence analytics to support pharmaceutical and diagnostic developers in making the critical strategic decisions necessary for success in the emerging field of precision medicine. Amplion believes that biomarkers are the key to realizing precision medicine. From drug R&D to disease diagnosis, the company recognizes that biomarkers can drive precision medicine. The only way to master the drug discovery and development process and harness the explosively growing data from biomarker research is to fully leverage large-scale biomarker intelligence analytics powered by machine learning.

Amplion specializes in leveraging advanced machine learning to read biological and scientific information sources, collecting, analyzing, and classifying the world’s biomarker knowledge. Amplion’s pharmaceutical and diagnostics clients have accelerated their biomarker-related research by 50% or more and tripled the success rate of clinical programs compared with previous approaches.

Currently, Amplion has established partnerships with pharmaceutical and diagnostic companies to continue leveraging its platform to discover new opportunities and achieve strategic objectives.

Amplion is led by CEO Chris Capdevila, Chief Product Officer Dr. Amanda Enstrom, and Chief Technology Officer Mike Harrington. Amplion is a platform that leverages intelligence, machine learning, and biomedical expertise to accelerate precision medicine. By harnessing biomedical evidence, it provides actionable insights for clinical solutions, enabling strategic decision-making in drug and diagnostic development.

Greycroft is a leading venture capital firm focused on investments in the internet and mobile markets. Greycroft’s CEO has access to the profiles of all partners and their associated areas of expertise. Leveraging an extensive network of media and technology connections to enhance visibility, thereby fostering strong strategic partnerships.

(Compiled by Xu Wenjuan)